Try our Advanced Search for more refined results
Life Sciences - April, 2015
369 articles
- NJ Doc Gets Year In Prison In $100M Lab Bribery Scheme
- Discovery Tightened In FTC's AbbVie Pay-For-Delay Suit
- Critics Call Newly Released Medicare Part D Data Confusing
- GOP Sens. Knock 'Opaque' FDA Stand On Biosimilars
- Cherokees Seek Share Of $2.4B Actos Deal On Behalf Of Tribes
- Glaucoma Drug Co. Hit With Class Action After Trial Tanks
- FDA To Investigate Hospital Hand Sanitizer Safety
- Mayer Brown Reps Dow Chemical In Latest Unit Sale For $860M
- Paul Weiss Fights Med. Co. Liquidator's Bid For Docs
- Amgen Tells Fed. Circ. Sandoz Would 'Gut' Biosimilar Law
- Agriculture Biotech Co. Arcadia Sets Sights On $100M IPO
- Allergan Asks Judge To Nix Off-Label Botox Suit
- Judge Won't Block FDA's Generic Abilify Approvals
- 5 Tips For Preparing Expert Witnesses In Products Cases
- Accredo Pays $45M To Escape Novartis Exjade Kickback Suit
- GSK Wants Info On Expert For Reed Smith Atty's Wife
- FTC Is No Longer DOJ's Little Brother In Antitrust Remedies
- ViroPharma Prescribes $8M To Cure Investor Suit
- Blueprint Medicines Upsizes IPO Amid Cancer Biotech Craze
- Biotech Exec Lauds Bill To Ease Small-Company Disclosures
- Dendreon Shareholders Lose Bid For Equity Committee
- 4 Tips To Help Your Client Ward Off Unwanted Advances
- FDA Says Abilify Promo Is Misleading
- Eli Lilly Keeps Employees' Salary Info From Cymbalta Suit
- Embattled Ariad CEO To Step Down In Sarissa Deal
- 3rd Circ. Tosses Fen-Phen Injury Suit Against Wyeth
- Chinese Pharma Co. Derivative Suit Premature, Judge Rules
- House Leaders Unveil Dialed-Back FDA Overhaul Bill
- Aveo Board Dumps Cancer Drug Derivative Suit
- Critics Rip Big Pharma Alternative To FDA Warning Label Plan
- TIG Gets Coverage For Stryker Knee Deals Capped At $6.2M
- GW Seeks To Grow Cannabinoid Products With $179M Offering
- Mylan Ups Perrigo Offer To $35.6B, But Rejected Again
- The Satisfaction Of A Refund, Or Your Class Action Back
- FDA Clears Abilify Generics Despite Otsuka Objections
- FDA Finalizes 3 Biosimilars Guidances
- Consumers Seek $5M In Suit Over 'Magical' Anti-Aging Serum
- Bipartisan Bill To Lift Veil On Fed. Settlements Reintroduced
- Washington Tribal Marijuana Pact Bill Heads To Governor
- Takeda Will Pay Up To $2.4B To Resolve Actos Suits
- Device Maker Accused Of Firing Accountant Over FCA Claims
- HTG Prepares To Test Investor Appetite For Diagnostics
- Novartis Unit Beats Cataract Lens Injury Suit
- Allergan Can Be Liable Under FCA In Kickback Suit, Gov't Says
- SAC Capital Ducks Investors' Racketeering Claims
- 5th Circ. Urged To Rehear Off-Label Reglan Claims
- Judge Says Tribal Court Should Hear Actos Suit
- FDA Launches Fresh Crackdown On Supplement Cos.
- Howmedica Pays $3M To End Sales Rep. Reimbursement Suit
- AstraZeneca And Damages In 'At-Risk' Generic Drug Launches
- TPP And The Next Frontier In International Arbitration
- Humana Urges Court Not To Allow Drug Cos.' Aggrenox Appeal
- Bayer Settles False Ad Suit Over WeightSmart Vitamins
- Fed. Circ. Remand Shows Nautilus May Have Little Impact
- Fed. Circ. Says Biosig Heart Monitor Patent Not Indefinite
- Impax Board Slams Investor Suit Over Compliance Gaffes
- Deals Rumor Mill: General Electric, Sobi, Caliber Midstream
- 5 Biotechs Set Stage For $415M Wave Of IPOs
- FDA Cracks Down On Medtronic Production Problems
- The Rising Stars Of Life Sciences Law
- Sandoz Fights Amgen's Bid To Halt 1st Biosimilar Launch
- Reed Smith Atty's Widow Slams GSK's Bid To Delay Trial
- Adaptimmune Set To Join Rush Of Cancer-Focused IPOs
- Baker & McKenzie Guides $109M Biocartis IPO
- FTC Warns Divestitures May Reach Beyond Problem Market
- Cooley Shows Off Life Sciences Dominance With Aduro IPO
- NJ High Court To Mull Preemption Battle In Reglan Claims
- INC Research's PE Backers Plan $237M Secondary Offering
- $16M Medical IP Judgment Relied On Witness Lies, Co. Says
- TWi, Takeda Settle Generic Dexilant Patent Suit
- Meunier Carlin Nabs Ex-King & Spalding IP Pro For Atlanta
- Supreme Court Rejects Teva's Reglan Preemption Dispute
- Celgene Grabs VC-Backed Cancer Biotech In $485M Deal
- CGL Policies In 4th Circ. May Cover Intentional Conduct
- IRS Slams Medtronic Bid To Seal Trial Docs In $561M Tax Row
- Mylan Nixes Teva's $40B Takeover Bid Amid Pharma Tussle
- The Latest In The Neverending Story Of Bard V. WL Gore
- HSBC, Deutsche, Barclays Led Antitrust Targets In 2014
- NY Southern District Becomes Antitrust Hotspot
- Dendreon Knocks Shareholders' Push For Equity Committee
- Former Pharma Exec Sues Inovio Over Stock Option Refusal
- Egyptian Diagnostic Co. Sets IPO Range For London Offering
- Biolitec's Contempt Fine Capped At $70M In IP Dispute
- Mylan's Sweetened $33B Perrigo Bid Gets Spurned
- Pharmacies Are Health Care Providers, Texas High Court Says
- Calif. County Defends Drug Cleanup Law To High Court
- Vinson Set To Lead Week's IPO Activity With 2 MLP Debuts
- PTAB Won't Review Chiesi Unit's 4 Hypertension Drug Patents
- Mylan Slapped With Patent Suit Over Generic Estrogen Patch
- EPA Agrees To Drop Superfund Suit For $1.7M Cleanup Costs
- Pa. Consumer Says Bayer's MiraLax Caused Kidney Damage
- National Storage, Apigee Mark Week's Only IPOs
- Bankruptcy Courts Remain Closed For Marijuana Businesses
- An Update On Hatch-Waxman Personal Jurisdiction Cases
- Protect Workers' Salary Info In Suit, Cymbalta Maker Says
- FDA Slams Supplement Cos. Over Untested Ingredient
- Sheppard Mullin Hires Ex-Greenberg Traurig M&A, Health Pro
- Vitacost Drops Beef With Ex-Counsel Over Botched IPO Docs
- Pfizer Near Settlement On Hormone Therapy Cancer Claims
- Celgene Drugs Join Hedge Fund's AIA Patent Hit List
- Weight Loss Biotech Gelesis Inches Closer To $52M IPO
- Why REMS Abuse Doesn't Belong In Antitrust Litigation
- Feds Hammer FedEx's Bid To Escape Pill Trafficking Charges
- MultiVir Sets IPO Terms Amid Run Of Cancer Biotech Debuts
- Allergan Pushes To Ax Eye Doctors' FCA Kickback Suit
- 5 Tips For Playing Both Sides Of The FCA Aisle
- Honigman Miller Snags Patent Pro For Ann Arbor Office
- Retailers Slam Pushback To Linking Effexor, Lipitor Appeals
- RB Recalls 1.5 Million Bottles Of Mislabeled Mucinex
- A Teva-Mylan Tie-Up Would Face Serious Antitrust Scrutiny
- Perrigo Wants Akorn's Antitrust Counterclaims Tossed
- GCs Name Most Elite Law Firms
- Hedge Fund's New Patent Attack Targets Biogen's MS Drug
- Prolias Blames PDI For Sinking Cornell Licensing Deal
- Millennium Must Pay Ameritox $8.6M In Patent Row, Jury Says
- Circumcision Clamp Makers Sued Over Amputated Penis
- Medtronic Win In 10th Circ. A Break For Device Cos.
- Enzo Investor Wants Co.'s Books In Wake Of Medicare Fraud
- Bio-Rad Investor Demands Books In Wake Of $55M FCPA Deal
- Rite Aid Wants To Join Lidoderm Patch Antitrust Battle
- Hedge Fund's Latest Patent Attack Targets Pharmacyclics
- Costco, 1-800 Contacts Stare Down Lens Makers In Utah
- Kirkland's Client Strategy Pays Off In Teva's Bid For Mylan
- Bristol-Myers Again Urges Justices To Assess Hepatitis Patent
- Warner Chilcott Beats Bayer's Infringement Claims In Yaz Suit
- Deals Rumor Mill: Baring Private Equity, Canon, BC Partners
- Medtronic Wins 10th Circ. Battle Against Infuse Injury Suit
- NY AG Says Doryx Dismissal Doesn't Doom Namenda Case
- House OKs Bill To Clarify Controlled Substance Oversight
- Fed. Circ. Won't Rehear Medtronic's IP Row With NuVasive
- FDA Fleshes Out Stance On Overseas Med Device Trials
- FDA Considers Heavier Regs For $2.9B Homeopathy Industry
- Troutman Sanders Adds Ex-Gordon & Rees Partner To IP Team
- Shasta Axes PharmaTech's $2M Glucose Strip Suit
- Brandon Capital Raises $154M For Aussie Biotech Ventures
- 3 Different Scenarios For Marijuana In Indian Country
- Schiff Hardin Snags IP, Pharma Pro From Winston & Strawn
- Teva-Mylan Deal Gains Traction As Perrigo Deal Is Rejected
- Cardinal Case Shines Light On FTC's Disgorgement Plans
- Roxane Says Jazz's Xyrem Patent Covers Law Of Nature
- J&J Says Costco Blind To Legality Of Contact Lens Pricing
- Pfizer Antibiotic Patent Escapes Apotex AIA Challenge
- FDA Bashes Otsuka Bid To Block Abilify Generics
- GNC Supplement Mislabeling Row Dropped By Plaintiff
- How To Prepare A Successful L-1 Visa Petition
- Cancer-Focused Blueprint Medicines Prepares $115M IPO
- GSK Dodges Avandia Side-Effect Disclosure Class Action
- Plaintiffs Say Shire Withholding Docs In Pay-For-Delay Suit
- Whistleblowers Appeal Dismissal Of Novartis FCA Xolair Suit
- Teva To Pay $512M To End Provigil Pay-For-Delay Dispute
- Daiichi Sankyo To Unload $3.6B Sun Pharma Stake
- 2015 Begins With A Drop In FCPA Enforcement Activity
- Drugmakers Slam FDA Study On Pill Shapes, Sizes
- FTC Inks 2nd Highest Disgorgement Deal With Cardinal Health
- A New Paradigm For Industrial Hemp Farming On Tribal Lands
- Tips For Guiding Your Client Through The Mediation Process
- The 100 Best Law Firms For Female Attorneys
- Law Firm Biases Continue To Thwart Women
- The Best Law Firms For Female Partners
- The Glass Ceiling Report
- High Court Urged To Reject Teva, Pliva Reglan Petitions
- J&J Can't Dodge $63M Verdict In Children's Motrin Case
- Otsuka Can't Pause Generic Abilify Launches, Judge Says
- AMS Settles More Than 350 Vaginal Mesh Suits
- Clifford Chance-Led REIT Set To Headline Week's 3 IPOs
- Cos. Say China Blocked Vitamin C Antitrust Suit Compliance
- State AGs Eying Pay-For-Delay Suits, Calif. Official Says
- FDA Should Ease Off-Label Regs Before Courts Do: PhRMA GC
- Jury Vindicates Pfizer In First Zoloft Birth Defect Trial
- 3rd Circ. Affirms Use Of Daubert To Fight Class Cert.
- Actavis Says 'Product-Hopping' Ruling Aids Namenda Appeal
- Drug Cos. Rip Bid To Merge Lipitor, Effexor Antitrust Appeals
- After FTC Fine, Cactus Juice Co. Loses Bid For Trademark
- Eli Lilly Beats Cymbalta Withdrawal Risk Suit
- Canadian High Court Squashes HIV Drug Securities Suit
- 7 Cos. Rake In $1.3B In Week's Flood Of IPO Activity
- Hony Capital Unloads $1.3B In Shares Of CSPC Pharma
- P&G Urges High Court To Stay Out Of Fixodent Evidence Claim
- MRI Radiation Therapy Maker ViewRay Pulls Plug On IPO
- Virginia's 'Rocket Docket' Continues To Roar
- DaVita To Settle FCA Suit After Witness Coaching Inquiry
- Pliva's Win In 5th Circ. Is A Blueprint To Beat 'Off-Label' Suits
- KemPharm IPO Raises $56M After Pricing Below Range
- Fla. House OKs 'Right To Try' Bill For Terminal Patients
- Law Firms Nix Hospital CEO's $60M Suit With 'Slam Dunk'
- Warner Chilcott Nabs Win In Generic Doryx Delay Row
- FTC To Dive Deep In Pay-To-Delay Analysis, Brill Says
- Deals Rumor Mill: Procter & Gamble, Hony Capital, Stemcor
- Natrol Buyer Tells Judge It Resolved Row With Ex-Owners
- WilmerHale Nabs Cooley Life Sciences M&A Pro In Palo Alto
- For Biosimilars Under Medicare, It Is Just The Beginning
- Ameritox Scores Jury Win In Urine Test Patent Row
- FTC Official Says Patent Settlement Side Deals Suspicious
- FTC Can Seek Disgorgement In Cephalon Suit, Judge Says
- FDA Pressed To Clarify Purity Standard On Injectables
- Medtronic Guts Over 140 Suits In Tenn. Federal Infuse Fight
- Abbott Wins Another Round In 20-Year Protein Patent Fight
- Cephalon Thins FCA Off-Label Marketing, Kickback Suit
- Otsuka Hits FDA With New Suit Over Abilify Generics
- Atty In NFLer's Stock Scheme Loses Insurance Defense Row
- Alibaba Sends Pharmacy Biz To Affiliate In $2.5B Deal
- Amgen Can't Halt Sandoz's Biosimilar Launch Ahead Of Appeal
- Rite Aid Hits Pharma Cos. With Generic Niaspan Antitrust Suit
- 2 Routes To Hourly Rates For Lawyers
- Clarus Nixes $86M IPO After Testosterone Drug Falls Flat
- A Prescription For Sound DEA Compliance
- Sidley Austin Adds Ex-O'Melveny M&A Pro in New York
- Branch Law Firm Says Former Atty Bound To Arbitrate Claims
- 3 Biotechs Rake In $272M In IPO Rush
- SIGA Asks Judge To Nix Financial Adviser's Legal Fee Claims
- Judge Allows Most Claims In Suboxone MDL To Move Forward
- Jones Day Urges 8th Circ. To Nix Training-Video Sanction
- FDA Panel Backs Safety Of AstraZeneca Diabetes Drug
- Bausch & Lomb, Alcon Challenge Utah Contact Lens Law
- FTC's Wright Slams Shortcuts In Evaluating IP Antitrust Claims
- Michael J. Fox Foundation Settles Over Spoiled Lab Samples
- Texas Firms Botched Case Against Bayer's Mirena, Suit Says
- HHS Inspector To Scrutinize Increased Generic Drug Costs
- ITC Can't Claim Digital Download Authority, Fed. Circ. Told
- PhRMA Presses Case For Dumping 340B Orphan Drug Rule
- Sullivan Guides $930M Private Sale Of China TCM Shares
- Enzo Says Fed. Circ. Ruling In Patent Row Flouts Teva
- Smith & Nephew Sued Over Failed Knee Replacement
- BakerHostetler Adds International Arbitration Partner In DC
- Rising Star: Sidley Austin's Jaime Jones
- Concordia Nabs $735M In Upsized Offering To Back Covis Buy
- Immuno-Oncology Biotech Aduro Boosts IPO Target To $119M
- Ex-Execs Of Co. Sold To J&J Charged With Securities Fraud
- Questcor Pays $38M To Settle Securities Class Action
- J&J Stays Clear Of Time-Barred FCA Claims, 3rd Circ. Rules
- 7th Circ. Revives Suit Over Abbott Off-Label Scheme
- DLA Piper Snags Another Morgan Lewis Atty For Philly Office
- Shire, Actavis Spar At Fed. Circ. Over Teva's Impact
- 2nd Circ. Wary Of Anti-Competitive Intent In Namenda Plan
- Galderma, Actavis Settle Generic Epiduo Suit Ahead Of Trial
- Teva Urges High Court To Review Disputed Labeling Theory
- Rising Star: Paul Hastings' Eric Dittmann
- 510(k) In Patent Litigation: Applicants Should Be Cautious
- How To Weather Media Inquiries In High-Profile Cases
- FDA Reverses Broad Abilify Approval, Otsuka Says
- Viking Therapeutics Sets Terms For Downsized $22.5M IPO
- W.Va. High Court Affirms 20 Zoloft Dismissals
- Geron Gets Shareholder Action Over Cancer Drug Trimmed
- Ropes & Gray, Jones Day Guide Week's 2 IPOs Raising $105M
- Etsy, Party City Lead $1.2B Pack Of IPOs Set To Break Lull
- Rising Star: Hogan Lovell's Adam Bellack
- Kramer Levin Snags 2 Life Sciences IP Pros In NY
- SEC Drops Probe Of Bankrupt Pharma Co. Dendreon
- Prograf Antitrust MDL Lawyers Seek $34M In Fees
- Will The Pendulum Swing Back In IPR Proceedings?
- Convicted Atty In Penny Stock Scam Can't Revisit SEC Ruling
- 5th Circ. Frees Pliva, Others From Generic Reglan Claims
- Judge Won't Sanction Skin Treatment Co. For 'Stinker' Ch. 11
- Merck Fights Bid To Strike Replies In K-Dur Pay-For-Delay Suit
- Fed. Circ. Affirms Sandoz Loss In Generic AzaSite Case
- Bayer Says Tossing Brain Supplement Suit Is A No-Brainer
- Edge Therapeutics Raises $72M For Brain Injury Drug
- P&G, Wal-Mart Escape Fixodent MDL After Experts Excluded
- Siga Creditors Seek Probe Of Execs' 'Bad Faith' Conduct
- Panel Sends Medical Marijuana Bill To Full Fla. Senate
- Booming Pharma Biz Means Big Money For Some Law Firms
- Valeant, Pershing End Spat With Allergan Over Takeover Bid
- Medtronic Urges Fed. Circ. To Toss NuVasive Surgery Patent
- Judge Grants Workers Expanded Data in Forest Sex Bias Suit
- 4 Tips For Keeping Civil FCA Suits From Going Criminal
- Rising Star: BakerHostetler's Lee Rosebush
- Some Declaratory Judgment Guidance For ANDA Litigants
- 2 Cases Audit Firm Defendants Can Rely On
- Zoloft Plaintiffs Face High Stakes In First Birth Defect Trials
- Abbott Wants GSK HIV Suit Axed Weeks Before Retrial
- P&G, Wal-Mart To End Fixodent MDL After Crushing Ruling
- FDA Fleshes Out Stance On Fast-Track Device Approvals
- Feds Must Add Details In Sanofi Insider Trading Case: Judge
- Purdue's Anti-Abuse OxyContin Patent Claims Found Invalid
- Biolitec Exec Still Ducking Depositions, Sanctions Bid Says
- Judge Chides FDA For Stalling Otsuka's Abilify Suit
- 3rd Circ. Says Comcast Forces Class Cert. Redo In Ex-J&J Suit
- Full Fed. Circ. Won't Review Standard In $1B Gore-Bard Suit
- Dendreon Slams Shareholders' Bid To Stay $495M Sale
- Fed. Circ. Affirms Another AbbVie Win In Humira Patent Case
- American Capital Pockets $750M In Mirion Technologies Sale
- Biotronik Fights Discovery Motion In $1.1M FCA Fees Row
- Mylan Makes $29B Bid To Buy Pharma Co. Perrigo
- 'Cosmeceutical' Classification In Regulatory Crosshairs
- Lessons From The 1st Biopharma Inter Partes Reviews
- AbbVie Says FTC Can't Fight By Own Rules In Pay-For-Delay
- Boehringer Asks DC Circ. To Rethink Doc Ruling In FTC Probe
- Texas, Feds Recover $25M From Glenmark For Inflated Prices
- Lead Plaintiff Drops DaVita Dialysis Claims
- JPML Centralizes 15 Suits Over Benicar Side Effects In NJ
- FDA Warns Hospira Again For Poor Practices In Italy
- 3rd Circ. Says Drug Cos. Can't Send Effexor Suit To Fed. Circ.
- NY Pharmacy Sues CVS Over Suspension, Withheld Money
- Intercept Raises $367M As More Biotechs Pursue Follow-Ons
- Fed. Circ. Affirms Most Of $76M AstraZeneca Prilosec IP Win
- UK Cancer-Focused Biotech Adaptimmune Eyes $150M US IPO
- Hedge Fund Adds Jazz Drug To List Of AIA Review Targets
- Calif. Biotech Eyes $86M IPO To Fund Muscular Dystrophy Med
- Accutane Ruling Could Have Ripple Effect Beyond NJ
- Ex-FDA Chief Named Institute Of Medicine's Foreign Secretary
- Rite Aid Files Latest Antitrust Suit Over Solodyn Generic Deals
- Spinal Therapy Co. Ducks Investor Class Action
- Twin City Needn't Cover Medical Co.'s FCA Suit, Judge Says
- Texas Court Says Latex Glove Maker Must Indemnify Dealer
- Vitamin Shoppe Says Studies Back Up Protein Labels
- Cannabis And Indian Country: Basics 101
- The 5 Biggest M&A Moves Of The 1st Quarter
- Drug Cos. Want 2nd Circ. To Hear Bid To Nix Aggrenox Claims
- Abbott Says FCA Suit Over Preapproval Promotion Fails
- FTC Aims To Limit Cephalon Evidence In Pay-For-Delay Trial
- Bristol-Myers Set To Partner With Gene Therapy Co. UniQure
- Novartis To Pay $12.3M, Royalties To End IP Row With Juno
- Wyeth, Teva Push To Move Effexor Appeal To Fed. Circ.
- Natrol Ch. 11 Buyer Sues Ex-Owners Over 'Sham' Contract
- High Court Won't Hear After-Acquired Evidence Use Appeal
- Novartis Defends Exelon Patents At Fed. Circ.
- 3 VC-Backed Drugmakers Fire Up $200M In IPO Plans
- AbbVie Tries To Get Shire Shareholders' Suit Tossed
- FDA Outlines Steps For Changing Drug Safety Controls
- Pain-Pump Seller, Ironshore Settle $10M Coverage Row
- Aduro Prepares $80M IPO After Inking Novartis Partnership
- 3rd Circ. Urged To Merge Lipitor, Effexor Antitrust Appeals
- Rite Aid Latest To File Aggrenox Pay-For-Delay Suit
- Fresenius Says Whistleblower Disclosures Are Already Public
- Merck Wants FCA Claim Tossed After Millennium Escapes Suit
- FDA Looks To Duck Firm's Suit Over J&J Risperdal Docs
- 3 Tips For Firms With Lawyers On Both Sides Of A Deal
- Class Says FDA Ruling Backs Nexium Pay-For-Delay Retrial
- Travelers Says No Duty To Defend Medical Co. In IP Suit
- Taxation With Representation: Wachtell, Simpson, Cooley
- Painkiller Developer Collegium Pharmaceutical Eyes $86M IPO
- Latham To Lead Week's Only IPO Expected To Top $50M
- FedEx Civil Suit Halted Pending Criminal Drug Investigation
- Teva Strikes $24M Deal To Exit Nexium Pay-For-Delay Suit
- Obesity Capsule Maker Wants $60M IPO After $22M Financing
- Fed. Circ. Urged To Rehear Medtronic's IP Row With NuVasive
- Medtronic Pays $4.4M To End Device Sale Investigation
- Aggrenox Doesn't Apply In Provigil Pay-For-Delay Suit: Teva
- NC Shutters Compounding Pharmacy, Recalls Drugs
- Takeda Calls $2.2B Actos Settlement Report 'Rumor'
- Diet Pill Maker, Snooki Can't Dodge False Ad Class Action
- Bryan Cave Can't Get Ex-Client's Docs In $1.5M Fee Row
- Shire Drugs Are Next Targets Of Hedge Fund's AIA Reviews
- Roche's New Accutane Warning Label OK, Judge Rules
- PharMerica Can't Nix FCA Suit Under First-To-File Bar
- Natrol Gets Green Light On Ch 11. Plan Disclosures
- State AGs Urge Lawmakers To Investigate Supplement Cos.
- CryoLife Appeals Rare Injunction In Patent Case
- Generic Cases Still Face Tough Odds After High Court Snub
- Pelvic Mesh Mass Tort Cases Can Stay In Philly, Judge Says
- NJ Doctors Get Prison Time In Lab Services Bribe Scheme
- Baxter, J&J Strike Deal To End Floseal Patent Fight
- Johns Hopkins Faces $1B Suit Over 'Horrific' Syphilis Study
- Novartis Docs Privileged In Kickback Case, Judge Says
- Penn Wins Atty Fees Under Octane In Alzheimer's Patent Suit
- FDA Finalizes Guidance On Abuse-Deterrent Narcotics
- Final Hagens Berman Thalidomide Claim Too Late, Judge Says
- FDA Must Block Off-Label Diabetes Drug Promos, Group Says
- Sarepta Therapeutics Securities Class Action Gets The Boot
- USC Settles Ex-Football Player's Pain Med Suit At 11th Hour
- Here's How The CARERS Act Could Change Cannabis Policy
- DLA Piper Lures Life Sciences Deal Maker From Morgan Lewis
- Novartis Faces Zometa Suit Despite Delay After Plaintiff Death
- Goodwin-Led Insulin Pump Maker Asante Pulls Plug On IPO
- Pfizer Dodges Centrum Multivitamin False Ad Class Action
- Nutrex, GNC, Others Sued Over Falsely Marketed Supplements
- Cochlear Gets New Trial After $131M IP Verdict
- So Your H-1B Petition Is Not Selected — What Now?
- Ethics In The Tech Age: What Every Lawyer Should Consider